United Therapeutics (UTHR) · Q2 2026 results and valuation

At 18.0% growth a year (3-year revenue growth), the model's fair value is $1091.88 a share — the stock trades 45% below it. Today's price assumes 9.1% growth a year.

1. Figure

   United Therapeutics has previously projected a $4 billion revenue run rate by the end of 2027 with its existing commercial portfolio.

2. Figure

   The company expects its revenue run rate to increase from $3 billion to $4 billion because each of the two products will exceed today's total revenues.

   Source quote

   “Each of the 2 products will exceed our total revenues of today, a revenue run rate of $3 billion going to $4...”

Management sounded noticeably less positive answering analysts than in its prepared script — a bigger drop than in 86% of calls. Scripts are polished in advance; a drop under questioning often marks the topics analysts pressed on, so the answers deserve a closer read than the script.

Sentences that drove the tone

“To round out this section, we believe the combination of record patient metrics, increased commercial reach, the strength of our differentiated portfolio and growing physician awareness positions us well to...”

“As these opportunities advance, we see a future in which our impact on patients, our industry and our growth trajectory can reach an entirely new level, making United Therapeutics a...”

“If successful, TETON-TPF would open the door to an even larger opportunity, at least double that of IPF, and position nebulized Tyvaso to become a leading therapy for patients with...”